NeuroMetrix (NURO) Competitors

In the previous week, Star Equity had 2 more articles in the media than NeuroMetrix. MarketBeat recorded 2 mentions for Star Equity and 0 mentions for NeuroMetrix. NeuroMetrix's average media sentiment score of 0.00 equaled Star Equity'saverage media sentiment score.

19.4% of NeuroMetrix shares are held by institutional investors. Comparatively, 3.8% of Star Equity shares are held by institutional investors. 7.3% of NeuroMetrix shares are held by company insiders. Comparatively, 33.5% of Star Equity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Star Equity has a net margin of -3.44% compared to NeuroMetrix's net margin of -203.71%. Star Equity's return on equity of -1.17% beat NeuroMetrix's return on equity.

Star Equity has a consensus price target of $16.50, indicating a potential upside of 71.61%. Given Star Equity's stronger consensus rating and higher possible upside, analysts plainly believe Star Equity is more favorable than NeuroMetrix.

NeuroMetrix has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, Star Equity has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.

Star Equity has higher revenue and earnings than NeuroMetrix. Star Equity is trading at a lower price-to-earnings ratio than NeuroMetrix, indicating that it is currently the more affordable of the two stocks.

NeuroMetrix has higher earnings, but lower revenue than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than NeuroMetrix, indicating that it is currently the more affordable of the two stocks.

In the previous week, TELA Bio had 4 more articles in the media than NeuroMetrix. MarketBeat recorded 4 mentions for TELA Bio and 0 mentions for NeuroMetrix. TELA Bio's average media sentiment score of 0.51 beat NeuroMetrix's score of 0.00 indicating that TELA Bio is being referred to more favorably in the news media.

TELA Bio has a net margin of -48.37% compared to NeuroMetrix's net margin of -203.71%. NeuroMetrix's return on equity of -42.56% beat TELA Bio's return on equity.

19.4% of NeuroMetrix shares are owned by institutional investors. Comparatively, 94.4% of TELA Bio shares are owned by institutional investors. 7.3% of NeuroMetrix shares are owned by company insiders. Comparatively, 4.7% of TELA Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

TELA Bio has a consensus price target of $2.20, indicating a potential upside of 97.31%. Given TELA Bio's stronger consensus rating and higher probable upside, analysts clearly believe TELA Bio is more favorable than NeuroMetrix.

NeuroMetrix has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500. Comparatively, TELA Bio has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500.

In the previous week, Nephros had 3 more articles in the media than NeuroMetrix. MarketBeat recorded 3 mentions for Nephros and 0 mentions for NeuroMetrix. NeuroMetrix's average media sentiment score of 0.00 equaled Nephros'average media sentiment score.

Nephros has a net margin of 6.35% compared to NeuroMetrix's net margin of -203.71%. Nephros' return on equity of 12.22% beat NeuroMetrix's return on equity.

Nephros has a consensus price target of $6.00, indicating a potential upside of 85.19%. Given Nephros' stronger consensus rating and higher probable upside, analysts clearly believe Nephros is more favorable than NeuroMetrix.

Nephros has higher revenue and earnings than NeuroMetrix. NeuroMetrix is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

19.4% of NeuroMetrix shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 7.3% of NeuroMetrix shares are owned by company insiders. Comparatively, 6.7% of Nephros shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

NeuroMetrix has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500. Comparatively, Nephros has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500.

In the previous week, Predictive Oncology had 3 more articles in the media than NeuroMetrix. MarketBeat recorded 3 mentions for Predictive Oncology and 0 mentions for NeuroMetrix. Predictive Oncology's average media sentiment score of 0.16 beat NeuroMetrix's score of 0.00 indicating that Predictive Oncology is being referred to more favorably in the media.

NeuroMetrix has a net margin of -203.71% compared to Predictive Oncology's net margin of -185,476.72%. Predictive Oncology's return on equity of 0.00% beat NeuroMetrix's return on equity.

NeuroMetrix has higher revenue and earnings than Predictive Oncology. NeuroMetrix is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 19.4% of NeuroMetrix shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by insiders. Comparatively, 7.3% of NeuroMetrix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Predictive Oncology has a beta of 3.45, meaning that its share price is 245% more volatile than the S&P 500. Comparatively, NeuroMetrix has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500.